These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Results of adjuvant interferon study in WHO melanoma programme. Cascinelli N; Bufalino R; Morabito A; Mackie R Lancet; 1994 Apr; 343(8902):913-4. PubMed ID: 7908370 [No Abstract] [Full Text] [Related]
8. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma. Johnson DM; Hayat SQ; Burton GV J Rheumatol; 1999 Apr; 26(4):1009-10. PubMed ID: 10229440 [No Abstract] [Full Text] [Related]
9. [High-dose interferon-alpha and adjuvant treatment of melanoma with poor prognosis: requiem for a drug marketing license?]. Saiag P Ann Dermatol Venereol; 1999 Mar; 126(3):211-3. PubMed ID: 10394432 [No Abstract] [Full Text] [Related]
10. Where are we with adjuvant therapy of stage III and IV melanoma in 2009? Fecher LA; Flaherty KT J Natl Compr Canc Netw; 2009 Mar; 7(3):295-304. PubMed ID: 19401062 [TBL] [Abstract][Full Text] [Related]
11. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Messori A; Becagli P; Trippoli S; Tendi E Eur J Cancer; 1997 Aug; 33(9):1373-9. PubMed ID: 9337677 [TBL] [Abstract][Full Text] [Related]
12. Comment on "Perhaps not everyone knows that...", (Ann Oncol 2001; 12: 1186). Sulkes A; Schachter J Ann Oncol; 2002 Apr; 13(4):637. PubMed ID: 12056717 [No Abstract] [Full Text] [Related]